Halozyme Therapeutics, Inc.

HALONASDAQHealthcare● Active

$70.73

$-0.80(-1.12%)

Market Cap$8.4B

P/E Ratio—

52W High$82.22

52W Low$51.06

Avg Volume1.6M

Open$71.59

Beta0.87

Net Income Financials Revenue

Halozyme Therapeutics, Inc. (HALO) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

HALO · net income · updated Jun 9, 2026

Core profitability metrics

HALO · net income · margin · TTM · CAGR

Net income was $316.9M for FY2025 (fiscal year ending 2025-12-31), down 28.6% year-over-year. Net profit margin was 22.7%. Based on available data, Halozyme Therapeutics, Inc. has been profitable since at least 2017.

FY2025 Net Income$316.9M▼ -28.6% YoY

Trailing 12M (TTM)$348.8Mtrailing 4 quarters sum

Net Profit Margin22.7%$316.9M ÷ $1.40B

YoY Change-28.6%—

5-Year CAGR+19.7%FY2020 → FY2025

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 9, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %★ First Profit: 2017

▸ FMP /income-statement · Annual · HALO net income history · HALO profit margin

Annual net income data

HALO · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025$316.9M▼ 28.6%22.7%$1.40B

FY2024$444.1M▲ +57.7%43.7%$1.02B

FY2023$281.6M▲ +39.3%34.0%$829.3M

FY2022$202.1M▼ 49.8%30.6%$660.1M

FY2021$402.7M▲ +212.0%90.8%$443.3M

Net income vs peers (Healthcare)

HALO vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

Halozyme Therapeutics, Inc.YOU

HALO

$316.9M-28.6%22.7%

Eli Lilly and Company

LLY

$20.64B+94.9%31.7%

77%

UnitedHealth Group Incorporated

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Halozyme Therapeutics, Inc. (HALO) reported net income of $316.9M for FY2025 (fiscal year ending 2025-12-31), down 28.6% year-over-year. The net profit margin was 22.7% — meaning the company kept $0.23 of every dollar of revenue as profit.

Based on available data, Halozyme Therapeutics, Inc. has been profitable since at least 2017. Net income reached a peak of $444.1M in FY2024. Data available for 15 fiscal years.

Halozyme Therapeutics, Inc.'s net profit margin was 22.7% for FY2025, based on the latest annual results.

Investors sometimes search for "Halozyme Therapeutics, Inc. net worth" — the company's market capitalization is a separate figure from HALO net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

HALO net income · 5 questions

Halozyme Therapeutics, Inc. is profitable. The company reported net income of $316.9M for FY2025, a net profit margin of 22.7%. Net income was down 28.6% year-over-year. Based on available data, Halozyme Therapeutics, Inc. has been profitable since at least 2017.

is HALO profitabledoes HALO make a profitHALO profitabilityHALO profitable company

▸ Source: FMP /income-statement · GAAP · Halozyme Therapeutics, Inc. · Halozyme Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026